Professor Dr Angus Dalgleish

BSc (hons), MB BS, MD ( UCL/UCH, University of London) Flying doctor service Mt Isa Queensland 1976 Medical registrar rotation PAH/PCH Brisbane. (1977-1980) Radiotherapy programme RBH 1981 Medical Oncology programme RPA and RNS Sydney 1982-83. Clinical research fellow to Prof R Weiss FRS at the ICR and hon registrar at the RMH, 1984-5. MRC Senior clinical research fellow at the CRC Northwick park, Hon consultant in General Medicine, Immunology and Medical Oncology. 1986-1991. Foundation professor of Oncology at St George's , University of London. 1992- Principal of the CVI now renamed the ICVI since 2000 FRACP FRCP FRCPath FMedSci Joshua Lederberg Prize from Celgene for work developing thalidomide analogues including Lenalidomide. Visiting Prof on Tumour immunology course at the Karolinska,  Sweden Visiting Prof at the Earle Chiles Institute , Portland , Oregon. USA. Visiting Prof at the University of Stellenbosch, South Africa. Main areas of interest; Immunotherapy  including cancer vaccines, dendritic cell vaccines, check point inhibitors, Non specific immune modulators including the IMiDs, Lenalidomide, Pomalidomide, LDN and IMM-101. Using sequential therapy to improve efficacy and reduce toxicity. HIV Pathogenesis and vaccine development. Viruses as the cause of cancer and the role of chronic inflammation in causation and progression of cancers. COVID pathogenesis and long COVID management. The importance of vitD3 in the management of cancer. Over 400 publications on pubmed, see pubmed/dalgleish a. Major paper on COVID pathogenesis and vaccine design only available on PMC downloaded over 220,000 times.

Immunotherapy Cancer vaccines. Immune modulators including the IMiDs (Lenalidomide) , LDN, IMM-101 Repurposed drugs including CBD and derivatives, Metformin, Valcyte etc